Raltitrexed

CHEMBL225071 Phase 4 Onaylandı Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

458.5 g/mol

LogP

1.4

Phase

4

Raltitrexed is a quinazoline folate analog that directly and specifically inhibits thymidylate synthase (TS) after intracellular polyglutamation, thereby depleting thymidine monophosphate and disrupting DNA synthesis and repair in rapidly dividing cells. It is used for the treatment of advanced colorectal cancer and has been investigated in mesothelioma and other malignancies.

Moleküler Ağırlık

458,5000 g/mol

LogP

1,40

TPSA

177,00 Å²

Lipinski RO5

Geçer

Terapötik Alanlar

Pancreatic Cancer Cardiovascular Disease Respiratory Disease Non-Small Cell Lung Cancer Chronic Obstructive Pulmonary Disease Alzheimer's Disease Parkinson's Disease Infectious Disease Gastroesophageal Reflux Disease Inflammatory Bowel Disease Chronic Kidney Disease Non-Alcoholic Fatty Liver Disease Prostate Cancer Colorectal Cancer Leukemia

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Yapı

SVG PNG

Cite this structure

Embed this structure

SMILES

Cc1nc(=O)c2cc(CN(C)c3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)s3)ccc2[nH]1

InChI

InChI=1S/C21H22N4O6S/c1-11-22-14-4-3-12(9-13(14)19(28)23-11)10-25(2)17-7-6-16(32-17)20(29)24-15(21(30)31)5-8-18(26)27/h3-4,6-7,9,15H,5,8,10H2,1-2H3,(H,24,29)(H,26,27)(H,30,31)(H,22,23,28)/t15-/m0/s1

Molecular Formula

C21H22N4O6S

HBD / HBA

4 / 9

Döndürülebilir Bağlar

9

Ağır Atomlar

32

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

Raltitrexed is a quinazoline folate analog that directly and specifically inhibits thymidylate synthase (TS) after intracellular polyglutamation, thereby depleting thymidine monophosphate and disrupting DNA synthesis and repair in rapidly dividing cells. It is used for the treatment of advanced colorectal cancer and has been investigated in mesothelioma and other malignancies.

Yes, Raltitrexed is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL225071. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 135400182. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Hasta dostu bilgi mi arıyorsunuz?

Raltitrexed PillFYI'da

Yapı

Hızlı Veriler

Formül: C21H22N4O6S

Dış Bağlantılar

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.